US Patent 6,444,652: Scope, Claim Structure, and HBV Patent Landscape
United States Patent 6,444,652 claims antiviral treatment and prophylaxis of hepatitis B virus (HBV) using β-L-nucleosides (notably β-L-2′-deoxycytidine and β-L-thymidine) with broad substitution at R (H through acyl/aryl/alkoxyalkyl/sulfonyl/amino-acid residue/mono-di-tri phosphate and “stabilized nucleotide” prodrug classes). The patent also claims combination/alternation regimens with marketed anti-HBV agents (3TC/FTC/L-FMAU/DAPD/famciclovir/penciclovir/entecavir/adefovir/lobucavir/ganciclovir/ribavirin). Dependent claims narrow to valinyl amino-acid prodrug variants and to ≥95% enantiomeric purity.
What is the core invention claim set?
Independent method claims (treatment and prophylaxis)
The patent’s independent claim backbone is a method of use for HBV treatment/prophylaxis by administering an “effective amount” of:
- Claim 1: β-L-2′-deoxycytidine (formula shown in patent) with substituent R defined broadly.
- Claim 2: β-L-thymidine (formula shown) with substituent R defined broadly.
- Claim 3: A combination method using the compounds together, where R is hydrogen or acyl.
- Claim 4: A combination/alternation method using a compound of the formula with broad R plus one or more listed anti-HBV drugs.
- Claim 5: Substantially duplicative to claim 4 in structure (same combination/alternation concept and same comparator list).
Independent composition and product claims
-
Claim 6: A compound claim covering the formula with R defined as H, mono/di/tri phosphate, amino-acid residue, acyl/alkyl, or a stabilized phosphate derivative (explicitly framed as a stabilized nucleotide prodrug).
-
Claim 17: Another compound claim to the formula (scope depends on the patent’s exact structure text, but it is used later as the basis for pharmaceutical compositions).
-
Claim 21: Another compound claim to the formula (likely another genus block tied to the β-L-2′-deoxycytidine vs β-L-thymidine scaffolding).
-
Claims 18, 19, 22, 23: Pharmaceutical composition claims with carriers, and optionally combined with another anti-HBV agent chosen from the same list (3TC/FTC/L-FMAU/DAPD/famciclovir/penciclovir/entecavir/adefovir/lobucavir/ganciclovir/ribavirin).
Method claims tied to specific prodrug substitution
- Claims 7 and 9: Method claims where R is an amino acid residue.
- Claims 8 and 10: Narrowing to L-valinyl (valine amino-acid residue).
- Claims 11 and 12: Combination method where R is hydrogen or an amino-acid residue, narrowed to L-valinyl.
- Claims 13-16: Combination/alternation method where R is amino-acid residue, narrowed to L-valinyl.
Enantiomeric purity narrowing
- Claim 33: β-L-2′-deoxycytidine is ≥95% in the “designated enantiomeric form.”
- Claim 34: β-L-thymidine is ≥95% in the designated enantiomeric form.
How broad is the claim scope by R-group and prodrug coverage?
R definition is the main breadth driver
Across claims 1, 2, 4, 5, 9, 13, and 15, the substituent R is defined as one of:
- H
- Carboxamides/acyclic and aromatic acyl-related classes:
- Ether-linked acyl/alkoxyalkyl:
- “—CO-alkoxyalkyl”, “—CO-aryloxyalkyl”
- Sulfonyl acyl analogs:
- “alkylsulfonyl”, “aryl sulfonyl”, “aralkylsulfonyl”
- Amino-acid residue (with dependent claims specifying L-valinyl)
- Phosphate variants:
- “mono, di, or triphosphate”
- Stabilized nucleotide (explicitly used as a prodrug concept)
Practical effect: This genus is not limited to a single prodrug (such as a known phosphoramidate) but sweeps in multiple prodrug modalities that deliver the active nucleotide after metabolic conversion, plus non-phosphate prodrug motifs (acyl/sulfonyl/amino-acid ester-like forms).
Stabilized nucleotide prodrug language
- Claim 6 explicitly includes “a stabilized phosphate derivative (to form a stabilized nucleotide prodrug).”
- This wording aligns with a broader patent practice in nucleoside therapies where phosphate groups are masked to improve oral bioavailability or cellular delivery.
What does the combination language actually cover?
Combination/alternation with listed HBV agents
Claims 4, 5, 13, 15 include a “combination or alternation” structure:
- Administer the β-L compound (with broad R)
- in combination or alternation with an effective amount of one or more selected anti-HBV agents from the listed group:
Listed agents (as written):
- β-L-2-hydroxymethyl-5-(cytosin-1-yl)-1,3-oxathiolane (3TC)
- cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (FTC)
- β-L-2′-fluoro-5-methyl-arabinouridine (L-FMAU)
- β-D-2,6-diaminopurine dioxolane (DAPD)
- famciclovir
- penciclovir
- 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one (entecavir, BMS-200475)
- 9-[2-(phosphono-methoxy)ethyl]adenine (PMEA, adefovir, dipivoxil)
- lobucavir
- ganciclovir
- ribavirin
Practical effect: If a β-L compound is used alongside any of these agents, the method claims are positioned to capture both:
- simultaneous fixed/regimen combinations
- sequence-based alternation (use at different times/visits)
Compositions paired with another agent
Claims 19 and 23 include composition-level combinations with “another anti-hepatitis B virus agent” selected from the same list. That creates potential enforcement hooks against:
- combination tablets/capsules
- co-packaged regimens, depending on how “composition” is interpreted and structured by formulation.
Where are the highest-risk subspaces for competitors?
1) Amino-acid prodrug variants (L-valinyl)
Competitor risk increases for β-L compounds where R is an amino-acid residue, particularly L-valinyl:
- Claim 8 / 10: method claims where R is L-valinyl
- Claim 12 / 14 / 16: combination and narrower L-valinyl embodiments
2) ≥95% enantiomeric purity manufacturing specs
- Claims 33 and 34 read on methods where the active is produced with high enantiomeric purity.
- This can matter for process design because meeting a purity spec can bring a product inside the narrowest dependent method claims even if the prodrug/formulation is outside the core genus.
3) Broad “stabilized nucleotide” and phosphate masking
- Competitors using masked phosphate prodrugs of the β-L nucleoside scaffold face a direct reading into:
- the “stabilized phosphate derivative” language (Claim 6)
- the “stabilized nucleotide” language in the R-group definitions (Claims 1, 2, 4, 5, etc.)
How are the claims layered? (enforcement map)
Claim tiers
| Tier |
Claim types |
What they capture |
Key breadth lever |
| T1 |
Independent method claims (1,2,3,4,5) |
Treatment/prophylaxis using β-L compounds alone or with other listed HBV agents (combination or alternation) |
R-group breadth + combination list |
| T2 |
Dependent methods (7-16) |
Amino-acid residue scope, L-valinyl, and combination embodiments |
Specific R narrowing (amino acid, L-valinyl) |
| T3 |
Dependent purity (33,34) |
High enantiomeric purity methods |
≥95% enantiomer spec |
| T4 |
Product and composition claims (6,17,18,19,21-24) |
Composition/formulation supply, including “optionally with carrier” and co-agent compositions |
Carriers + optional co-agent list |
Enforcement posture
- Method claims typically drive use-based licensing and litigation against regimen choices.
- Composition/product claims create enforcement hooks against manufacturing and formulation, especially where co-formulation is performed.
What is missing for a full “landscape” without further patent text?
This request targets “scope and claims and patent landscape” for US 6,444,652. The provided prompt contains only the claim text you pasted; it does not include the bibliographic record (filing/publication numbers, assignee, priority dates), specification, prosecution history, cited references, or related-family identifiers. Without those, a complete and accurate landscape (co-pending continuations, family members, priority chain, terminal disclaimers, overlaps with later HBV nucleoside/prodrug patents, and litigation status) cannot be constructed from reliable primary sources.
Accordingly, the analysis below stays strictly within what is proven by your claim text: invention scope, claim construction logic, competitor risk subspaces, and mapping to the drug class and combination list appearing in the claims.
Landscape implications based on the claimed HBV regimen list
The comparator list is the roadmap
The patent’s combination set includes multiple widely used HBV therapeutics spanning:
- Nucleoside analog RT inhibitors: 3TC (lamivudine), FTC (emtricitabine), famciclovir, penciclovir, lobucavir, ganciclovir, ribavirin
- Adenosine/guanosine analogs and phosphonate prodrugs: entecavir, adefovir/dipivoxil (PMEA derivatives)
- Other listed agents: L-FMAU, DAPD
Business implication: The patent’s combination claims are designed to cover HBV treatment strategies using the then-standard nucleoside/prodrug regime space rather than a narrow single-drug pairing.
Competitive positioning
A company developing a β-L nucleoside/prodrug in HBV with:
- ≥95% designated enantiomer
- L-valinyl amino-acid residue variant
- masked phosphate/stabilized nucleotide forms
- use in combination/alternation with any agent from the listed comparator set
faces high read-through risk against the method tiers (claims 1,2,4,5, and the dependent L-valinyl and purity claims).
Key Takeaways
- US 6,444,652 claims HBV treatment and prophylaxis using β-L-2′-deoxycytidine and β-L-thymidine with an R-group that is broad across acyl/sulfonyl/amino-acid (including L-valinyl), phosphate/prodrug, and stabilized nucleotide forms.
- The patent covers combination or alternation with a defined set of anti-HBV agents, including 3TC, FTC, entecavir, and adefovir derivatives, plus additional nucleoside antivirals explicitly enumerated in the claims.
- Dependent claims narrow on two high-signal product/process subspaces: L-valinyl amino-acid residue and ≥95% enantiomeric purity (claims 33 and 34).
- Product/composition claims extend scope beyond method-only use into formulation and co-agent combination.
FAQs
1) What is the single largest determinant of claim breadth in this patent?
The R group definition (H through acyl/aryl/alkoxyalkyl/sulfonyl/amino-acid residue/phosphate and “stabilized nucleotide” prodrugs) drives whether a compound/prodrug falls within multiple method and product claims.
2) Do the method claims require simultaneous dosing?
No. Claims 4, 5, 13, and 15 use “combination or alternation,” which covers both simultaneous and sequence-based regimens.
3) Which dependent claims are most likely to capture specific commercial prodrug variants?
The amino-acid residue claims and their L-valinyl narrowing (claims 8, 10, 12, 14, 16) are the most direct for prodrug identity-by-structure.
4) How does enantiomeric purity enter the claim scope?
Claims 33 and 34 require that the β-L compound used in the method is at least 95% in the designated enantiomeric form.
5) Do the claims include composition-level coverage with carriers?
Yes. Claims 18, 19, 22, and 23 include pharmaceutical compositions comprising the compound with a pharmaceutically acceptable carrier, and optionally with another listed anti-HBV agent.
References
[1] United States Patent 6,444,652. (Claim text as provided in the prompt).
